Literature DB >> 15239667

Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro against HIV-1 wild type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations.

Romano Silvestri1, Marino Artico, Gabriella De Martino, Giuseppe La Regina, Roberta Loddo, Massimiliano La Colla, Massimo Mura, Paolo La Colla.   

Abstract

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) active against NNRTI-resistant mutants were obtained by introducing two methyl groups at positions 3 and 5 of the benzenesulfonyl moiety of L-737,126 (1) and coupling one to three glycinamide/alaninamide units to its carboxyamide function. In cell-based assays, the new derivatives showed activities against HIV-1 wild type and NNRTI-resistant mutants [Y181C, K103N-Y181C, and triple mutant (K103R, V179D, P225H) highly resistant to efavirenz] superior to that of the parent indole derivative 1.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15239667     DOI: 10.1021/jm031147e

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  High potency of indolyl aryl sulfone nonnucleoside inhibitors towards drug-resistant human immunodeficiency virus type 1 reverse transcriptase mutants is due to selective targeting of different mechanistic forms of the enzyme.

Authors:  Reynel Cancio; Romano Silvestri; Rino Ragno; Marino Artico; Gabriella De Martino; Giuseppe La Regina; Emmanuele Crespan; Samantha Zanoli; Ulrich Hübscher; Silvio Spadari; Giovanni Maga
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

2.  Prevalence of primary resistance at baseline in acutely and recently infected subjects enrolled in AIDS clinical trials group protocol 371.

Authors:  Carrie Dykes; A Lisa Mukherjee; Ronald J Bosch; Elizabeth Connick; Paul A Volberding; Lisa M Demeter
Journal:  J Acquir Immune Defic Syndr       Date:  2010-09       Impact factor: 3.731

3.  Novel Cyclopropyl-Indole Derivatives as HIV Non-Nucleoside Reverse Transcriptase Inhibitors.

Authors:  Mohammad Hassam; Adriaan E Basson; Dennis C Liotta; Lynn Morris; Willem A L van Otterlo; Stephen C Pelly
Journal:  ACS Med Chem Lett       Date:  2012-05-02       Impact factor: 4.345

Review 4.  N-Pyrrylarylsulfones with High Therapeutic Potential.

Authors:  Valeria Famiglini; Sabrina Castellano; Romano Silvestri
Journal:  Molecules       Date:  2017-03-09       Impact factor: 4.411

Review 5.  A review on recent developments of indole-containing antiviral agents.

Authors:  Ming-Zhi Zhang; Qiong Chen; Guang-Fu Yang
Journal:  Eur J Med Chem       Date:  2014-10-23       Impact factor: 6.514

6.  Design, Synthesis and In Vitro Evaluation of Spirooxindole-Based Phenylsulfonyl Moiety as a Candidate Anti-SAR-CoV-2 and MERS-CoV-2 with the Implementation of Combination Studies.

Authors:  Assem Barakat; Ahmed Mostafa; M Ali; Abdullah Mohammed Al-Majid; Luis R Domingo; Omnia Kutkat; Yassmin Moatasim; Komal Zia; Zaheer Ul-Haq; Yaseen A M M Elshaier
Journal:  Int J Mol Sci       Date:  2022-10-06       Impact factor: 6.208

Review 7.  Indolylarylsulfones, a fascinating story of highly potent human immunodeficiency virus type 1 non-nucleoside reverse transcriptase inhibitors.

Authors:  Valeria Famiglini; Romano Silvestri
Journal:  Antivir Chem Chemother       Date:  2018 Jan-Dec

Review 8.  Synthetic strategies, SAR studies, and computer modeling of indole 2 and 3-carboxamides as the strong enzyme inhibitors: a review.

Authors:  Gholamabbas Chehardoli; Asrin Bahmani
Journal:  Mol Divers       Date:  2020-05-12       Impact factor: 2.943

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.